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Down syndrome (DS) is a common genetic condition caused by the presence of three
copies of chromosome 21 (trisomy 21). This greatly increases the risk of Alzheimer
disease (AD), but although virtually all people with DS have AD neuropathology by 40
years of age, not all develop dementia. To dissect the genetic contribution of trisomy
21 to DS phenotypes including those relevant to AD, a range of DS mouse models
has been generated which are trisomic for chromosome segments syntenic to human
chromosome 21. Here, we consider key characteristics of human AD in DS (AD-DS), and
our current state of knowledge on related phenotypes in AD and DS mouse models. We
go on to review important features needed in future models of AD-DS, to understand this
type of dementia and so highlight pathogenic mechanisms relevant to all populations at
risk of AD.
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Introduction: AD-DS, the Most Common Genetic Form of AD
Down syndrome (DS) is a complex, heterogeneous disorder caused by the presence of an extra copy
of human chromosome 21. Trisomy 21 is a common condition, with an incidence of 1 in 750 live
births (Parker et al., 2010). Prevalence in many countries is growing due to increasing maternal age,
the greatest risk factor for DS (Loane et al., 2013), together with rises in DS life expectancy (Yang
et al., 2002; Bittles and Glasson, 2004). In Northern Europe, for example, the number of people aged
over 40 years with DS is approximately double what it was in 1990, and in the UK this age group
accounts for a third of the estimated 40,000 people with DS (Wu and Morris, 2013).
The clinical presentation of DS varies extensively and includes features present in all individuals,
such as cognitive deﬁcits, and those seen in only some people, such as heart defects (Zigman, 2013;
Jensen and Bulova, 2014). Alzheimer disease (AD) pathology is found in the brains of virtually all
people with DS by 40 years of age (Wisniewski et al., 1985; Mann and Esiri, 1989), and trisomy 21
causes an increased risk of dementia such that approximately one third of the DS population has
AD (“AD-DS”) by the age of 60, with an estimated lifetime prevalence of 90% for all people with DS
(Prasher and Krishnan, 1993; Holland et al., 1998; Coppus et al., 2006; Margallo-Lana et al., 2007;
McCarron et al., 2014). However, while AD-DS is one of the largest contributors to morbidity and
mortality in DS (Coppus et al., 2008), not all individuals develop dementia, even by 70 years of age
(Krinsky-McHale et al., 2008; Ghezzo et al., 2014). Thus, the DS population has the most common
genetic form of early-onset AD, caused by trisomy 21. Studying AD-DS allows investigation of the
initial pathogenic events leading to AD and the development of dementia, relevant to both people
with DS and to the general population.
One approach to dissecting human disease is through studying mouse models, and a
large number of transgenic strains have been generated to understand speciﬁc aspects of AD
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pathology, most of which have human gene mutations that give
rise to rare early-onset familial Alzheimer disease (FAD; Braidy
et al., 2012;Webster et al., 2014). In the last decade, chromosome
engineering techniques have enabled the generation of an array
of DS mouse models that will allow us to dissect the genetic
contribution of chromosome 21 (Hsa21), or regions of the
mouse genome syntenic to Hsa21, to DS phenotypes. These
models recapitulate a wide range of DS features, including
neurobiological, behavioral and aging-related aspects (Zhang
et al., 2012b; Ruparelia et al., 2013). Thus, in the study of AD-DS,
mouse models of DS oﬀer an increasingly important approach
to understanding pathogenic mechanisms, so informing us about
pathways and networks relevant to all populations at risk of
dementia.
Here, we present an overview of clinical features of AD-DS,
compared to other genetic forms of AD, to highlight human
phenotypes that may be assessed in mechanistic studies of mouse
models. We then give examples of data from DS mouse models
compared to transgenic mice modeling aspects of AD pathology,
to illustrate informative ﬁndings from both types of model. We
also oﬀer examples of potentially helpful data for investigating
AD-DS from the outcomes of overexpressing single genes from
Hsa21. Finally, we consider the important features for mouse
models to enhance our understanding of AD-DS, and therefore
the pathogenetic mechanisms relevant to all AD. For brevity,
citations may not necessarily be the original papers, but useful
reviews or later references.
Genetic Forms of AD, Including AD-DS
The APP gene lies on Hsa21 and encodes the amyloid precursor
protein that is at the heart of the amyloid cascade hypothesis of
Alzheimer disease (Glenner andWong, 1984; Hardy andHiggins,
1992; Hardy and Selkoe, 2002). This hypothesis was generated
partly from the observation that extracellular plaques in brains of
people with AD are composed of Aβ peptides that are products
of APP metabolism. The hypothesis suggests that abnormal APP
metabolism initiates AD pathogenesis by triggering a set of events
that result in Aβ aggregation, particularly of the Aβ42 peptide,
in these extracellular plaques. This leads to the formation of
intracellular neuroﬁbrillary tangles, primarily composed of the
protein tau, and eventually loss of synapses and neurons. The
relationship between the histopathological features of AD and
dementia is not yet clear (Castellani and Perry, 2014).
The amyloid cascade hypothesis is currently the most widely-
accepted paradigm guiding investigations of AD pathogenesis,
and is supported at least in part by the rare cases of FAD caused
by diﬀerent mutations in APP, and in the presenilin genes PSEN1
and PSEN2 that aﬀect APP processing. APP mutations may, for
example, result in an increase in total Aβ production, or a relative
increase in Aβ species associated with pathogenicity (Ryan and
Rossor, 2010).
Importantly for understanding AD-DS, the link between APP
and AD also extends to gene dose: in rare forms of FAD,
duplication of the wildtype APP locus alone (“Dup-APP”) is
suﬃcient to cause highly penetrant early-onset AD (Rovelet-
Lecrux et al., 2006; Sleegers et al., 2006). Dup-APP cases
demonstrate that the three doses of APP arising from trisomy 21
are likely to be causative for AD-DS. Conversely, although very
rare, partial trisomy 21 excluding APP (i.e., with two “doses” of
APP) does not appear to lead to AD (Prasher et al., 1998; Korbel
et al., 2009).
While people with DS and Dup-APP are at high risk of
dementia, presumably in both cases because of APP triplication,
there are some intriguing diﬀerences in their AD-related clinical
features (Wiseman et al., 2015). Examining the eﬀects of
diﬀerent APP genotypes may therefore provide insights into the
modulation of APP pathogenesis. Table 1 shows key examples of
phenotypes in AD-DS and how these compare with Dup-APP,
FAD due to other APP mutations (primarily point mutations)
and late-onset sporadic AD (SAD). Mutations in PSEN1 and
PSEN2, which do not map to Hsa21, are not included.
However, a diﬃculty in analysing phenotypes is the
considerable heterogeneity in clinical presentation within
each APP genotype, even within families with the same
mutation. For example, there is a wide variety of non-cognitive
symptoms and behavioral changes across all four AD genotypes,
including personality changes (Nelson et al., 2001; Ball et al.,
2008), hallucinations (Sleegers et al., 2006; Basun et al., 2008;
Guyant-Marechal et al., 2008), paranoia (Sleegers et al., 2006;
Pilotto et al., 2013), and delusions (Burns et al., 1990), some
of which are associated with cognitive decline (Adams and
Oliver, 2010). Another important issue in diagnosing AD
in AD-DS is that dementia is an additional cognitive deﬁcit
acquired on top of the baseline cognitive impairment found
in people with DS: distinguishing between cognitive deﬁcits
due to intellectual disability, and decline at early stages of
AD, is therefore an important challenge. However, diagnosis
of dementia by experienced clinicians has been shown to be
accurate in DS, and even more reliable than recent operational
dementia criteria (Sheehan et al., 2015). Further, a few clinical
features stand out in AD-DS—a striking example, albeit one
of unknown relevance to AD, is seizure susceptibility in
adulthood, which appears heightened by APP duplication, as
both AD-DS (84%) and Dup-APP (57%) have signiﬁcantly
higher rates of seizures than SAD (10–20%). This may indicate
speciﬁc pathways that are progressively disrupted by APP
duplication, resulting in damaging electrical activity in the
brain.
Dup-APP and FAD caused by APP mutations are relatively
rare, and much information about these conditions remains to
be gathered, for example, on synaptic dysfunction, oxidative
stress and neuroinﬂammation. In contrast, AD-DS arises in
a population with a well-deﬁned genetic basis and a sizeable
prevalence, which means it is of great value for investigating AD
pathogenesis for everyone at risk of dementia.
Modeling DS, Including AD-DS, in Mice
Human chromosome 21 has synteny with the mouse genome,
such that its ortholog genes are found in three blocks with
conserved order and gene orientation on mouse chromosomes
10 (Mmu10), Mmu16, and Mmu17 (Hattori et al., 2000; Dierssen
et al., 2009); the mouse App gene lies on Mmu16 (Figure 1).
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Mice with precisely-deﬁned trisomies (or monosomies) have
been generated, now usually by chromosome engineering (Brault
et al., 2006; Tybulewicz and Fisher, 2006), to provide a set of
models that are segmentally trisomic for regions orthologous to
Hsa21 (Davisson et al., 1993; Sago et al., 1998; Olson et al., 2004;
Li et al., 2007; Herault et al., 2009; Pereira et al., 2009; Yu et al.,
2010a; Liu et al., 2011, 2014; Brault et al., 2015).
Generating many models with diﬀerent partial trisomies
creates a mapping panel in which individual phenotypes may be
assessed in several strains, and so assigned to speciﬁc trisomic
chromosomal region(s). As all DS phenotypes presumably arise
from abnormal gene dosage, candidate genes that when present
in three copies give rise to all or part of the phenotype, can be
chosen from the trisomic critical region. Individual candidate
genes can then be studied, for example, in overexpression or
knockout models, to assess the eﬀects of diﬀerent copy numbers
of the gene. Figure 1 is an overview of DS mouse models and
the chromosomal segments for which they are trisomic. Table 2
details the gene content for each DS mouse model shown,
including protein-coding and non-protein-coding genes relevant
to human trisomy 21.
The most complete mouse model to date,
Dp(10)1Yey/+;Dp(16)1Yey/+;Dp(17)1Yey/+, is trisomic for
all Hsa21 syntenic regions and was generated by crossing three
DS mouse models, each carrying duplications of the respective
Hsa21 orthologous regions on Mmu10, Mmu16 and Mmu17
(Li et al., 2007; Yu et al., 2010a,b; Figure 1). However, the vast
majority of studies relating to AD-DS have been performed on
the Ts65Dn mouse, as this has been an extremely important
“standard model” of DS for many years, prior to the development
of newer strains by chromosome engineering (Davisson et al.,
1993; Reeves et al., 1995; Table 2). The Ts65Dn mouse carries
a Robertsonian translocation resulting in trisomy of ∼42% of
the protein-coding genes orthologous to Hsa21, but it also has
79 additional genes (including long non-coding sequences)
from Mmu17 that are outside the Hsa21 region of synteny, and
these need to be taken into account when analysing phenotypes
(Duchon et al., 2011; Reinholdt et al., 2011). These extra
triplicated genes that do not relate to DS happen to include non-
Hsa21 genes, such as SYNJ2 and TIAM2 that have Hsa21/Mmu16
paralogues (SYNJ1, TIAM1), which may complicate phenotype-
genotype correlations (Duchon et al., 2011). Other triplicated
genes in Ts65Dn irrelevant to DS include several genes encoding
dynein light chains that may inﬂuence endosomal traﬃcking,
and so potentially aﬀect neuronal phenotypes (Hartley et al.,
2015).
A diﬀerent type of mouse model of DS is the “humanized”
transchromosomic “Tc1” mouse that carries a freely-segregating
Hsa21 (O’Doherty et al., 2005), which is functionally trisomic
for ∼75% of Hsa21 protein-coding genes (Gribble et al.,
2013). However, this extra chromosome is rearranged, and lost
stochastically at diﬀerent rates in diﬀerent mouse tissues—thus,
Tc1 mice are mosaic for the human chromosome. With respect
to AD research, the APP gene is not functionally trisomic in Tc1
mice because of a rearrangement that has occurred by chance, so
this animal expresses just the two endogenous copies of mouse
App (Sheppard et al., 2012).
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FIGURE 1 | Human chromosome 21 (Hsa21), orthologous mouse chromosomes (Mmu), and key mouse models of Down syndrome. Diagram
representing Hsa21 and its alignment with syntenic regions on Mmus 16, 17, and 10. The orange circle represents the human centromere and mouse models are
color-coded and aligned according to the chromosomal segment for which they are trisomic. Numbers in brackets represent the number of protein-coding Hsa21
orthologous genes within each region or mouse model, according to Ensembl release 79 and the breakpoints published in papers referenced here. The Tc1 mouse is
the only model which carries Hsa21, though genomic rearrangements and deletions (indicated by breaks in the chromosome) mean the mouse is functionally trisomic
for only ∼75% of Hsa21 genes (Gribble et al., 2013). All other mouse models carry duplications of mouse orthologues. The Dp1(16)Yey;Dp1(17)Yey;Dp1(10)Yey (or
Ts1Yey;Ts3Yey;Ts2Yey) mouse was generated by crossing together three partial trisomy models (Yu et al., 2010a) and spans the entirety of the Hsa21-syntenic
regions. The Ts65Dn mouse (Davisson et al., 1993) contains a freely segregating segment of Mmu16, however it is also trisomic for 43 extra protein-coding genes on
the centromeric section of Mmu17 that are not relevant to DS (indicated by an asterisk (*) and accompanying text box; Duchon et al., 2011; Reinholdt et al., 2011).
The Ts1Cje mouse (Sago et al., 1998) also contains a monosomy of eight protein-coding genes on Mmu12, irrelevant to the DS phenotype (indicated by “#” and
accompanying text box. Gene numbers are based on Ensembl release 79, compared to the original seven monosomic genes detailed in Duchon et al., 2011). Other
mice are Ts1Rhr or Dp1(16)Rhr mice (Olson et al., 2004); Ts1Yah mice (Pereira et al., 2009); Ts3Yah (previously published as Ts2Yah; Brault et al., 2015); and Ts4Yah
mice (previously published as Ts3Yah mice; Herault et al., 2009). Other useful examples of mouse models include the Ts43H model (not shown) which is partially
trisomic for Mmu17 including some genes with ortholog on Hsa21 (Vacík et al., 2005). The scale is in megabase pairs (Mb).
While many DS mouse models have been published,
there is no single complete model, and the usefulness of
these strains lies in their comparative and complementary
use in studying genotype-phenotype relationships, including
AD-related phenotypes (Table 3). These studies enable us
to map critical dosage-sensitive genes because each locus
is likely expressed at trisomic levels, mimicking human DS
transcription. We can also study the interactions of Hsa21
dosage-sensitive genes with the rest of the genome (Hsa21
and non-Hsa21), as well as eﬀects exerted by aneuploidy
per se.
Modeling Amyloid Deposition in Mice
In contrast to the segmental duplication of tens of endogenous
wildtype genes in DS mouse strains, AD models are primarily
transgenic lines that overexpress one or more of the human
mutant genes that cause FAD. These transgenes usually
insert at random sites in the genome and may be driven
by artiﬁcial promoters (see examples in Table 4), which
vary in terms of their spatial and temporal expression
patterns, and result in expression at often 5–10 fold
compared to endogenous mouse orthologue (Balducci and
Forloni, 2011; Hall and Roberson, 2012). Overexpressing
wildtype human APP or mouse App does not result in
amyloid deposition (Elder et al., 2010); hence the need to
use known AD-causative mutant sequences in transgenic
mice.
In general, while mutant APP transgenic mice develop robust
amyloid deposition, synaptotoxic features and memory
impairments, none of them reproduces tau-containing
neuroﬁbrillary tangles, the hallmark pathology of ADwhichmost
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TABLE 4 | Human APP overexpressing transgenic mice referred to in this review (information obtained from Alzforum.org).
Mouse Mutation Promoter Genetic Background References
APP22 APP751 KM670/671NL (Swedish),
V717I (London)
Human THY1 C57BL/6 Sturchler-Pierrat et al., 1997
APP23 APP751 KM670/671NL (Swedish) Mouse Thy1 C57BL/6 Sturchler-Pierrat et al., 1997
APP(V717I) APP695V717I (London) Mouse Thy1 Originally generated on FVB/N background;
available at reMYND as C57BL/6xFVB/N
Moechars et al., 1999
Tg2576 APP695 KM670/671NL (Swedish) Hamster prion protein C57BL/6;SJL mixed background Hsiao et al., 1996
TgCRND8 APP KM670/671NL (Swedish),
V717F (Indiana)
Hamster prion protein C3H/He-C57BL/6 mixed background Chishti et al., 2001
PDAPP APP V717F (Indiana) Human PDGF C57BL/6 x DBA2 Games et al., 1995
closely correlates with dementia (Hall and Roberson, 2012). The
combined overexpression of mutant APP and mutant human
tau is required to reproduce both amyloid and tau pathology,
although these tau mutations in humans do not alone cause
AD but another form of neurodegeneration, frontotemporal
dementia. Mutant APP transgenics may be best considered
models of APP/Aβ pathology (amyloid deposition) rather than
full AD.
Studying AD-DS Phenotypes in Mice
In Table 3, we summarize examples of ﬁndings that may be
informative for AD-DS from diﬀerent DS (mainly Ts65Dn) mice
and examples of AD models (Table 4). With respect to AD, a
wide range of mutant APP transgenic strains are available in
the literature, so we have chosen a few well-known examples
[APP22, APP23, APP (V717I), PDAPP, Tg2576, TgCRND8] to
illustrate some potential phenotypes of interest. We note that
the expression of wildtype mouse APP, and wildtype or mutant
human APP protein in these diﬀerent models can inﬂuence
amyloid pathology (Kokjohn and Roher, 2009). For example,
because of amino acid diﬀerences between the two species, mouse
APP may be processed with little BACE1 cleavage and so may
yield three times less Aβ than wildtype human APP (De Strooper
et al., 1995). In addition, the genetic background of AD mouse
strains aﬀects a range of APP/Aβ phenotypes, including plaque
deposition, APP metabolism, survival, and seizure rates (Carlson
et al., 1997; Lehman et al., 2003; Krezowski et al., 2004; Lassalle
et al., 2008; Rustay et al., 2010; Jackson et al., 2015). Similarly,
phenotypes observed in DS mice may be inﬂuenced by genetic
background (O’Doherty et al., 2005; Galante et al., 2009; Costa
et al., 2010; Deitz and Roper, 2011; Haydar and Reeves, 2012).
We consider only APP transgenic models of AD, as the other
genes used in such models (PSEN1, PSEN2, and MAPT) are not
encoded on Hsa21, and therefore are not directly relevant to
AD-DS.
In studying mouse phenotypes to understand AD-DS, we
are presented with two key issues. Firstly, we need to test
longitudinally DS models to look for changes in older mice
that are not apparent early on, and so may indicate aging or
neurodegenerative processes rather than neurodevelopmental
deﬁcits. Secondly, we need to separate normal aging processes in
DS from those connected speciﬁcally to AD-DS. The thoughtful
use of the increasing range of diﬀerent mouse models is enabling
us to dissect these issues to further our understanding of AD-
DS.
A study that has addressed both (1) neurodegenerative vs.
neurodevelopmental and (2) normal aging vs. AD phenotypes
has been performed in the Ts65Dn mouse. This study concerned
the neurodegenerative phenotype loss of basal forebrain
cholinergic neurons (BFCNs), and was carried out through
an experimental design involving optimal crossing of diﬀerent
mouse models and assessment of the genetically-distinct progeny
(Salehi et al., 2006). Firstly, Salehi and colleagues quantiﬁed the
known loss of BFCNs in Ts65Dn mice, and showed this loss to
be progressive, thus an aging or an AD-related phenotype in
this DS mouse model. The authors then compared BFCN loss
in Ts65Dn and Ts1Cje DS mouse models (Figure 1), and were
able to map a dosage-sensitive critical region that had to contain
a candidate gene for this phenotype: Ts65Dn mice lose BFCNs
but Ts1Cje mice turned out to have no loss compared to wildtype
mice. Therefore, the dosage-sensitive gene(s), that when present
in three copies is responsible for BFCN loss, must map within
the region of trisomy present in Ts65Dn but not in Ts1Cje. A key
candidate in this region was the App gene. By crossing Ts65Dn
mice to heterozygous App knockout mice, the authors generated
cohorts of progeny that carried the trisomic region with either
two or three copies of wildtype App. Assessing BFCN loss in
these cohorts led to the conclusion that the phenotype arises
mainly from having three copies of App and, further, that it is
associated with impairments in nerve growth factor retrograde
transport, linked to early endosomes, which are enlarged (Salehi
et al., 2006).
Given the role of APP triplication in this phenotype, there
is likely a strong link to AD and AD-DS. In people with early
AD pathology or mild cognitive impairment, neuroﬁbrillary
pathology has been detected in BFCNs (Mesulam et al., 2004;
Grudzien et al., 2007), while their loss has been observed
in patients with SAD (and other neurodegenerative disorders;
Zarow et al., 2003). Interestingly, enlarged early endosomes
have been detected in cortical tissues from cognitively intact
individuals with mild AD pathology, and in young individuals
Frontiers in Behavioral Neuroscience | www.frontiersin.org 12 October 2015 | Volume 9 | Article 268
Choong et al. AD and DS in mice
with DS (under 12 years old), suggesting that endosome
enlargement is an early feature in ADpathogenesis (Cataldo et al.,
2000).
DS Models in the Study of Candidate
Genes Influencing AD
As illustrated in Table 1, while people with DS have three
copies of APP and develop early AD neuropathology, their
clinical presentation is variable, suggesting that other genetic
and environmental factors inﬂuence pathogenesis. In addition to
APP, many genes on Hsa21 have been studied in the context of
neurodegeneration and/or AD, and it is conceivable that a three-
copy dose of any of these genes could contribute to disease and
dysfunction.
Single gene overexpressing transgenics do not model DS, or
AD-DS, but may provide some insights if carefully considered.
For example, seizures and neuronal network abnormalities
remain challenging areas to investigate but important phenotypes
to be explored in DS, AD-DS, and APP overexpression models
of AD (i.e., which are single gene transgenic models). In SAD,
seizures have been associated with early cognitive decline (Vossel
et al., 2013), while the incidence of seizures in AD-DS is
high and is associated with increased risk of dementia (for
example, McCarron et al., 2014). To date, seizure phenotypes and
epileptiform activity have been characterized across numerous
APP transgenic mice (Born, 2015), but it is unclear whether these
phenotypes are primarily driven by amyloid overproduction
(Mucke and Selkoe, 2012) or are an eﬀect of unphysiological
APP overexpression during development (Born et al., 2014).
Antiepileptic drugs, such as levetiracetam, which improve
seizures in DS (Sangani et al., 2010) and in AD (Cumbo and
Ligori, 2010), also ameliorate synaptic and memory dysfunctions
in APP transgenic mice by suppressing neuronal network
dysfunction (Sanchez et al., 2012; Devi and Ohno, 2013).
So, while single gene transgenic models do not model human
trisomy 21 or AD because they usually express the gene by
many-fold, from ectopic promoters, they oﬀer insights into
some of the functional consequences of overexpression, albeit
at non-trisomic levels. Table 5 presents a list of Hsa21 gene
candidates, in chromosomal order, that have been investigated
for overexpression-related phenotypes linked with AD across
diﬀerent mouse, fruitﬂy, and cellular models. We also compare,
where data are available, how related changes in these genes have
been explored in humans with AD and/or DS. Making optimal
use of mouse genetics, some of the single-gene-overexpressing
mouse transgenics have been crossed with AD models, to
look for changes in phenotypes that may be informative. For
example, crossing an S100β overexpression model with the
Tg2576 APP transgenic mouse generates double mutant progeny
with exacerbated cerebral amyloidosis and reactive gliosis. This
suggests that increased expression of S100β could contribute
to AD pathogenesis possibly by promoting amyloidogenic APP
processing (Mori et al., 2010).
Other key Hsa21 gene candidates DYRK1A and RCAN1
have been linked to AD pathogenesis through their eﬀects on
tau. The toxic neuroﬁbrillary tangles (NFTs) that accumulate
in AD are formed of hyperphosphorylated tau protein.
Overexpression of DYRK1A in transgenic mice resulted in tau
hyperphosphorylation (Ryoo et al., 2007, 2008), and DYRK1A
has been shown to co-localize with NFTs more frequently in
AD-DS brain compared to SAD (Wegiel et al., 2008). Similarly,
overexpression of RCAN1 in amousemodel resulted in abnormal
tau hyperphosphorylation (Wegiel et al., 2011). This suggests
that the increased expression of DYRK1A and RCAN1 in DS
could promote the formation of NFTs, a hallmark feature of AD
pathology.
Triplication of Hsa21 genes in DS does not necessarily lead
to a 1.5-fold increase (compared to euploid individuals) in their
RNA or protein expression. For example, a study in DS fetal
cortical tissue revealed multiple Hsa21 proteins in fact expressed
at similar or lower levels than in disomic controls (Cheon
et al., 2003a,b,c,d). Assessments at transcriptomic and proteomic
levels, together with meta-analysis across these studies, provide
useful resources for understanding patterns of alteration in gene
expression (for example, see Vilardell et al., 2011). As a few of the
studies in Table 5 have demonstrated, it is important to verify the
eﬀect of trisomy on candidate gene expression, in relevant tissues
and contexts, before further characterization of any potential
downstream eﬀects of trisomy.
Prospects for Research
Individuals with DS manifest the most common genetic form
of AD, and this undoubtedly largely arises from expressing
three copies of APP (Ness et al., 2012; Hartley et al., 2015).
Therefore, studying and modeling this population will assist in
understanding the contribution of APP to AD pathogenesis,
and evaluating the amyloid cascade hypothesis. However, the
variation in clinical presentation of AD-DS shows that many
other genetic and environmental factors contribute, almost
certainly including protective factors. The thoughtful use of
models will thus provide insight into these factors.
To study mouse models of AD-DS, it is critical to dissect
neurodevelopmental from neurodegenerative eﬀects (Bothwell
and Giniger, 2000; Contestabile et al., 2010). To be of interest
for AD-DS, such phenotypes should diﬀer from normal aging
in the mouse strain of interest, although this can be diﬃcult
to determine, particularly as DS has been characterized as a
syndrome of accelerated aging in both clinical (Lott, 2012;
Zigman, 2013) and epigenetic terms (Horvath et al., 2015),
and because aging remains the clearest non-genetic risk factor
for all forms of AD (Fratiglioni, 1996; Bush and Beail, 2004).
The longitudinal study of cognitive decline in DS mice poses
similar challenges to those in people with DS, and tests
need to distinguish between dysfunction due to dementia, as
opposed to aging or baseline learning deﬁcits. For example,
variations of a learning procedure involving incremental
repeated acquisition tasks suggest that declining performances
by Ts65Dn mice with age may be due to motor impairments
and/or decreased motivation, rather than neurodegenerative-
related eﬀects (Sanders et al., 2009). To improve behavioral
testing in mouse models of AD-DS, a potential avenue to explore
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TABLE 5 | Single gene overexpression models from Hsa21, with relevance to AD phenotypes. Genes are listed in order from centromere to Hsa21q
telomere.
Hsa21 gene Phenotypes studied in models Phenotypes studied in humans
APP Please refer to Table 3. Please refer to Table 1
SOD1 SOD1 overexpression protects against APP-induced lethality in transgenic
mice (Carlson et al., 1997)
SOD1 activity positively correlates with levels of memory functioning in DS
adults (Zis et al., 2012)
ITSN1 Overexpression of ITSN1 homolog nla in combination with SYNJ1 and
RCAN1 homologs causes impaired vesicle recycling in Drosophila (Chang
and Min, 2009)
ITSN1 protein (Hunter et al., 2011) and mRNA (Pucharcos et al., 1999)
elevated in DS
ITSN1 highly expressed in AD brain (Blalock et al., 2004; Wilmot et al., 2008)
SYNJ1 Mice overexpressing SYNJ1 have deficits in synaptic transmission (Voronov
et al., 2008)
SYNJ1 levels higher in DS brain tissue compared to controls, and elevated
in AD-DS cases (Martin et al., 2014)
SYNJ1 transgenic mice display enlarged endosomes (Cossec et al., 2012)
OLIG2 Neural progenitors from Olig2-overexpressing mice exhibit impairments in
neural progenitor proliferation (Lu et al., 2012)
SNPs in OLIG2 associated with psychotic symptoms in AD (Sims et al.,
2009)
RCAN1 RCAN1 overexpression in a mouse model causes abnormal tau
phosphorylation (Wegiel et al., 2011)
RCAN1 chronically elevated in AD and DS (Ermak et al., 2001)
In cell models, RCAN1 overexpression leads to deficits in synaptic
transmission (Martin et al., 2012) and promotes neuronal apoptosis (Sun
et al., 2011, 2014)
DYRK1A DYRK1A overexpression linked to tau hyperphosphorylation and increased
Aβ production in transgenic mice (Ryoo et al., 2007, 2008) and cellular
models (Park et al., 2007; Coutadeur et al., 2015)
Dyrk1a overexpression causes phosphorylation of PS1, increasing
γ-secretase activity in cells and stabilizing γ-secretase complex in mice (Ryu
et al., 2010)
Mouse Dyrk1a overexpression in TgDyrk1A mice results in a significant
reduction of Rest mRNA (Canzonetta et al., 2008)
DYRK1A increased in the brains of patients with AD (Kimura et al., 2007)
and DS (Ryoo et al., 2008)
DYRK1A expression in DS brain correlates with 3-repeat tau levels (Shi
et al., 2008; Wegiel et al., 2011)
Plasma DYRK1A positively correlates with cerebrospinal fluid tau and
phospho-tau in AD patients (Janel et al., 2014)
Co-localization of DYRK1A with NFTs greater in AD-DS than SAD (Wegiel
et al., 2008)
REST levels correlate with cognitive preservation and longevity in aging and
are downregulated in AD (Lu et al., 2014)
DSCAM Trisomy of Dscam in Drosophila results in synaptic targeting errors
(Cvetkovska et al., 2013)
DSCAM overexpressed in a DS patient, and DSCAM immunoreactivity
associated with Aβ plaques in demented DS patients (Saito et al., 2000)
ETS2 Ets2 transgenic mice and fibroblasts overexpressing ETS2 have elevated
APP, presenilin1 protein and increased Aβ production (Wolvetang et al.,
2003b)
ETS2 immunoreactivity associated with intracellular Aβ and
hyperphosphorylated tau in both AD-DS and sporadic AD brain tissue
(Helguera et al., 2005)
Ets2 overexpression causes apoptosis via caspase 3 activation in primary
neuronal cultures (Wolvetang et al., 2003a) and in DS cortical neurons
(Helguera et al., 2005)
BACE2 BACE2 overexpression in vitro reduces Aβ levels (Sun et al., 2006)
In a mouse model, overexpression of BACE2 has no effect on Aβ
production (Azkona et al., 2010a,b)
BACE2 polymorphisms may predict age of onset of dementia in DS
(Myllykangas et al., 2005; Mok et al., 2014)
ABCG1 ABCG1 overexpression stimulates cholesterol efflux in vitro (Kim et al.,
2007; Tansley et al., 2007) and either reduces (Kim et al., 2007) or increases
Aβ production (Tansley et al., 2007), the latter through an increase in APP
processing
ABCG1 gene upregulated in patients with DS (Tansley et al., 2007; Kong
et al., 2015)
ABCG1 gene expression unaltered in AD (Tansley et al., 2007)
ABCG1 overexpression in a mouse model has no effect on reference or
working memory or synaptic plasticity (Parkinson et al., 2009), nor alters Aβ,
APOE nor cholesterol efflux in vivo (Burgess et al., 2008)
CSTB Cstb overexpression in a mouse model does not induce epileptic activity or
a myoclonic seizure phenotype (Brault et al., 2011)
CSTB protein unaltered in DS fetal cerebral cortex (Cheon et al., 2003b).
(Continued)
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TABLE 5 | Continued
Hsa21 gene Phenotypes studied in models Phenotypes studied in humans
SUMO3 SUMO3 overexpression in cell culture systems shown to both increase
(Dorval et al., 2007) and reduce (Zhang and Sarge, 2008) Aβ levels
High molecular weight SUMO3 conjugates decreased in AD brain tissue
(Lee et al., 2014)
SUMO3 overexpression modulates APP processing, increasing the
CTF/APP ratio in vitro (Dorval et al., 2007)
S100β S100β application results in tau hyperphosphorylation in cultured neural
stem cells (Esposito et al., 2008)
S100β overexpression increases neuronal death and reduces neuronal
production in DS stem cells (Lu et al., 2011)
S100β overexpression in Tg2576 AD mice increases Aβ deposition and
BACE1 activity (Mori et al., 2010)
Mice overexpressing S100β show accelerated signs of aging (Shapiro and
Whitaker-Azmitia, 2004) neuropathology (Shapiro et al., 2004) and
behavioral deficits (Borella et al., 2003)
S100β upregulated in DS and AD (Griffin et al., 1989; Sheng et al., 1994)
S100β overexpression positively correlates with age in DS patients (Royston
et al., 1999)
SOD1, superoxide dismutase1; ITSN1, intersectin 1; SYNJ1, synaptojanin 1; OLIG2, oligodendrocyte transcription factor 2; RCAN1, regulator of calcineurin 1; DYRK1A, Dual specificity
tyrosine-phosphorylation-regulated kinase 1A; DSCAM, Down syndrome cell adhesion molecule; ETS2, V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 2; BACE2, beta-site
APP cleaving enzyme 2; ABCG1, ATP-binding cassette sub-family G member 1; CSTB, cystatin B; SUMO3, small ubiquitin-like modifier 3; S100β, S100 calcium binding protein β;
REST, repressor element-1 silencing transcription factor.
capitalizes on the association of dementia with deﬁcits in episodic
memory. The development of tests based on, for example, visuo-
spatial data, should therefore highlight age-dependent, dementia-
related deﬁcits in mouse models, because they rely on the
encoding and binding of information spontaneously, and do not
challenge other cognitive domains (Iordanova et al., 2009).
As well as the hypothesis-driven study of AD-DS phenotypes,
one of the greatest strengths of working withmousemodels is our
ability to undertake unbiased hypothesis-generating research,
by mapping phenotypes to genomic critical regions using the
range of strains now available. These include chromosome-
engineered panels of partially trisomic mice (Figure 1) as
well as single gene knockout animals, such as the App+/−
heterozygous mice, which may be crossed to partially trisomic
strains, to generate progeny with altered single gene copy
numbers on diﬀerent trisomic region backgrounds. The cohorts
of progeny from these crosses provide ideal groups for
testing the contributions of single Hsa21 genes to AD-
DS.
Mouse genome engineering continues to oﬀer new models
and approaches for teasing apart AD-DS relevant phenotypes,
and new strains are being published regularly to help reﬁne
experimental strategies. For example, the recent genomically
humanized NLF mouse (Saito et al., 2014), which has human
amino acid residues at key sites within APP that aﬀect its
processing, may yield new insights into the biology of both
AD and AD-DS, partly through expressing mutant APP at
physiological levels. The strategic breeding of new APP models
with DS segmental trisomies will contribute to determining
which phenotypes are downstream of an amyloid cascade.
Furthermore, independent study of partial trisomies without
three copies of App may help tease out eﬀects of other factors,
for example oxidative stress, cholesterol metabolism or immune
system dysfunction, in the development of dementia (Wiseman
et al., 2015).
DS mouse models also give us the ﬂexibility to investigate
the eﬀects of potentially dosage-sensitive non-coding regions.
For example, microRNAs (miRs)—short (20–23 nucleotide)
RNAs that downregulate the transcription of target genes—have
increasingly been investigated in AD pathogenesis due to their
diﬀerential regulation in molecular pathways associated with AD
(Veerappan et al., 2013). Hsa21 encodes 29miRs (MirBase release
21, Griﬃths-Jones, 2004), and their potential overexpression in
trisomy may contribute to genetic dysregulation relevant to AD-
DS. Overexpression of the Hsa21-encoded miR-155 in DS has
been reported to increase Aβ production via the downregulation
of sorting nexin 27, a membrane-traﬃcking component found in
early endosomes, that modulates γ-secretase activity (Wang et al.,
2013, 2014).
Hsa21 also encodes genes involved in post-translational
histone modiﬁcation, including DYRK1A, ETS2, HMGN1,
BRWD1, and RUNX1 (Dekker et al., 2014), which may be
investigated for their potential roles leading to the aberrant
histone modiﬁcations observed in AD (Zhang et al., 2012a;
Narayan et al., 2015). Histone methylation (speciﬁcally
H3K4me3) has been shown to correlate highly with genome-wide
domains of dysregulated gene expression in DS, which are highly
conserved between humans and Ts65Dn mice (Letourneau et al.,
2014). DSmouse models therefore model epigenetic structures in
humans and may be used to study the eﬀects of its dysregulation
in AD-DS.
Finally, mouse model research must be undertaken in parallel
with other rapid advances in the AD-DS ﬁeld. The advent
of human induced pluripotent stem (iPS) cells (Hunsberger
et al., 2015) for DS provides for the ﬁrst time a trisomic
human in vitro model that recapitulates hallmarks of some AD
pathology (Shi et al., 2012; Chang et al., 2015; Moore et al.,
2015; Murray et al., 2015). The further development of this
technology (Hunsberger et al., 2015) will prove valuable to
phenotyping and drug target discovery, alongside in vivo research
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and in vitro primary cultures from DS mice. An increasing call
is being made for partnerships to build up large cohorts of, and
biobanks from, people with DS for the systematic longitudinal
study of AD-DS progression (Hartley et al., 2015). In-depth
phenotypic studies across development with infants and adults
with DS are already underway (Wiseman et al., 2015). These will
allow greater power to identify biomarkers for the prediction
of AD in this large, genetically well-deﬁned population, for
example, through plasma (Dekker et al., 2015; Schupf et al., 2015),
cerebrospinal ﬂuid (Portelius et al., 2014a,b), and neuroimaging
studies (Beacher et al., 2009; Landt et al., 2011; Powell et al.,
2014; Sabbagh et al., 2015). Biomarker studies are also being
performed in AD models, including at very early phases of
Aβ deposition (Maia et al., 2015). Extending these studies to
mouse models of DS and AD-DS will contribute to elucidating
the genotype-phenotype relationships that ultimately lead to
dementia.
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